CRISPR Therapeutics
CRSP
39.10
+0.17
+0.44%
CRISPR Therapeutics
US · CRSP
#2057 by market cap
Listed 2016
39.10
+0.17
+0.44%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:54
Recent news
-
Rating change
Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/11/9
-
UBS Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $52Market Newswire · 2026/11/10
-
Rating change
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $50 to $110Market Newswire · 2026/11/4
-
Company notice
CRISPR Therapeutics | SCHEDULE 13G/A: OthersSEC · 2026/11/14
-
Rating change
Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Raises Target Price to $90Market Newswire · 2026/11/4
-
Rating change
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70Benzinga · 2026/11/4
-
Rating change
Crispr Therapeutics Price Target Raised to $90.00/Share From $88.00 by CitigroupDow Jones · 2026/11/5
-
Rating change
Crispr Therapeutics Price Target Maintained With a $82.00/Share by NeedhamDow Jones · 2026/11/3
-
Company notice
CRISPR Therapeutics | SCHEDULE 13G: OthersSEC · 2026/11/10
-
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $82Market Newswire · 2026/11/10
-
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswire · 2026/11/10
-
Company notice
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/7
-
Rating change
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90Benzinga · 2026/11/5
-
Rating change
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price TargetBenzinga · 2026/11/3
-
Rating change
Crispr Therapeutics Is Maintained at Buy by CitigroupDow Jones · 2026/11/5
-
Rating change
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $80Market Newswire · 2026/11/4
-
Company notice
CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities- Sakhamuri SivakesavaSEC · 2026/11/3
-
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients With Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026GlobeNewswire · 2026/11/9
-
Company notice
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sakhamuri SivakesavaSEC · 2026/11/7
-
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $67 to $110Market Newswire · 2026/11/10
-
Rating change
Crispr Therapeutics AG (CRSP) Receives a New Rating From a Top AnalystTipRanks · 2026/10/15
-
Rating change
Crispr Therapeutics Initiated at Neutral by UBSDow Jones · 2026/10/16
-
Company notice
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Silver Andrew JacobSEC · 2026/10/29
-
Rating change
Crispr Therapeutics Price Target Announced at $52.00/Share by UBSDow Jones · 2026/10/16
-
Rating change
H.C. Wainwright Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80Market Newswire · 2026/10/9
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:54:43 · For reference only, not investment advice and not tailored to your situation.
CRISPR Therapeutics discussion 0 comments